top of page

MEET HücreCELL® BIOTECHNOLOGY

H%C3%9CCRECELL_ICON_-__%C3%87al%C4%B1%C5
OUR STORY
H%C3%9CCRECELL_ICON_-_-03_edited.png
OUR PROJECT

HücreCELL® Biotechnology was established with the "Induced Pluripotent Stem Cell (iPSC)-based Diabetes Disease Model" R&D project #2200299, which was carried out and successfully completed between 01.11.2020 and 30.04.2022 within the scope of TÜBİTAK 1512 - Individual Young Entrepreneur (BIGG) Technoenterprise Capital Support Programme, and continues to be supported by R&D project #7238013 titled "Investigation of Tissue Damage at the microRNA (miRNA) and Exosomal miRNA Levels in iPSC-based Diabetes Disease Models and Determination of Potential Biomarkers", to be carried out between 01.07.2023 and 30.11.2024 within the scope of TÜBİTAK 1507 - SME R&D Initial Support Program.

"Induced Pluripotent Stem Cell (iPS) Diabetes Model"

H%C3%9CCRECELL_ICON_-_-02_edited.png
WHO ARE WE?

Pharmaceutical research is a difficult process that takes many years and creates a serious financial burden on researchers. The difficult process of a drug molecule's arrival from the proof-of-concept stage to the clinic sometimes leads to a delayed recognition that the molecule in question is ineffective or harmful as the stages are overcome. In the meantime, research has already been done on a large number of animals and humans. In addition, since there are important differences between animal and human organisms, molecules sometimes fail to show their profile in the animal exactly or as it should be. Testing drug molecules in human-like models at an early stage has a great advantage in terms of health expenditures, public health and access to appropriate treatments.

Induced pluripotent stem cells (iPSCs) are important components of regenerative medicine applications that allow human diseases to be set up in small plastic containers under laboratory conditions. The iPSC-derived disease models, obtained in line with certain quality and stability standards, become the most suitable environment for testing drug molecules at an early stage,with their ability to mimic the human organism. iPSC-derived disease models are advantageous not only in the early stages of drug research, but also by helping to reduce the burden at every stage of the molecules' journey to the clinic. Thus, it appears as a safe alternative with fewer animals and fewer human trials.

Our Founder and Chair, Pelin Kılıç, PhD has made it a principle to include her "Local Animal Protection Officer" identity, which she has been maintaining within the Ankara Metropolitan Municipality since September 2018, to her researcher identity. Within the scope of the first scientific project carried out in our company, she is committed to contributing to the protection of the living rights and habitats of animals by aiming to reduce the use of animal experiments and to spread the cruelty-free product movement in other studies in the scientific world.

OUR ORGANIZATION'S UNITED NATIONS SUSTAINABLE DEVELOPMENT GOALS

GOAL 3: GOOD HEALTH AND WELL-BEING

GOAL 8: DECENT WORK AND ECONOMIC GROWTH

GOAL 9: INDUSTRY, INNOVATION AND INFRASTRUCTURE

GOAL 17: PARTNERSHIPS FOR THE GOALS

bottom of page